Hemorrhagic and thrombotic complications in patients with myeloproliferative diseases

• Autor(a) principal: Vignal,Carla Valladares
• Data de Publicação: 1997
• Outros Autores: Lourenço,Dayse Maria, Noguti,Maria Aparecida Eiko, Chauffaille,Maria de Lourdes Ferrari, Kerbauy,José
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: São Paulo medical journal (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31801997000600004
• topic: Myeloproliferative Diseases; Hemorrhage; Thrombosis; Bleeding time; Platelet aggregation

OBJECTIVE: To correlate the incidence of hemorrhage and thrombosis to bleeding time (BT) and platelet aggregation in 27 consecutive patients with myeloproliferative diseases (MPD). DESIGN: Retrospective study. SETTING: Public tertiary referral center. PATIENTS: Eighteen patients with chronic myelogenous leukemia (CML), 5 with polycytemia vera (PV), 2 with essential thrombocytemia (ET) and 2 with idiopathic myelofibrosis (MF). Duke's BT and epinephrine-induced platelet aggregation were performed on the patients and on 10 healthy individuals. RESULTS: Eleven patients presented symptoms (41 %): 9 with hemorrhage (33%) and 5 with thrombosis (19%).There were less symptomatic patients in the CML group (28%) than in the other MPD (67%), without statistical significance (Fisher, p=0.06). Duke's BT was longer in symptomatic patients (Mann-Whitney, p<0.05). Platelet aggregation was abnormal in 7 patients (26%) and 71% of them were symptomatic (Fisher, p = 0.07). CONCLUSIONS: The high incidence of bleeding and thrombosis in patients with MPD was related to prolonged BT, but not to platelet aggregation abnormalities.